1. Basale insulineanalogen: voordeel bij type 2 diabetes
HbA1c gelijk, minder hypo (RR=0.66 – 0.84)
The discussion is soon narrowed to the level of evidence based medicine, and from that angle the only advantage of long-acting analogues is the reduced incidence of hypo they carry. Hypo: 3.6 confirmed. 0.5 hypo per patient year less, does that justify twice the price?
So minor advantages, but does evidence base capture everything?
Horvath et al. Cochrane System Rev 2007 Apr 18;(2):CD005613
Mullins et al. Clin Ther 2007; 1607 1